The purpose of the study is to assess the potential therapeutic effect of N-acetylcysteine "NAC" in COVID 19 patients.
This is a phase 3 trial enrolling subjects with newly diagnosed Corona virus disease 2019 ( COVID-19) infection who are classified as moderate cases and require hospitalization. Patients meeting eligibility criteria will be randomized either to receive oral N-acetylcysteine or not along with the institution treatment protocol . Treatment efficacy will be assessed using certain endpoints as follows: 1. Markers of inflammation and oxidative stress 2. Length of hospital stay 3. Need for ventilation 4. Mortality rate
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Oral formulation: 600 mg sachets of N-acetylcysteine
Al Assema Hospital
Cairo, Egypt
Change in TNF alfa level from baseline
The mean change in TNF alfa is used to assess NAC efficacy
Time frame: from enrollment till the end of treatment at 2 weeks or until hospital discharge or death
Change in IL-6 level from baseline
The mean change in IL-6 level is used to assess NAC efficacy
Time frame: from enrollment till the end of treatment at 2 weeks or until hospital discharge or death
Change in glutathione peroxidase level from baseline
The mean change in glutathione peroxidase is used to assess NAC efficacy
Time frame: from enrollment till the end of treatment at 2 weeks or until hospital discharge or death
Length of hospital stay
Duration of hospital stay for admitted patients
Time frame: Through study completion ( average 9 months)
Need for mechanical ventilation
Whether a patient required mechanical ventilation (intubation) or not
Time frame: Through study completion ( average 9 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.